Cabazitaxel versus enzalutamide/abiraterone in CARD eligible mCRPC patients with or without germline HRR defects.

Nuria Romero Laorden,Rebeca Lozano,Casilda Llacer Perez,José Manuel Rodríguez,Javier Puente,David Lorente,Ana Medina,Carlo Cattrini,Francesca Vitrone,Elena Almagro,Pablo Borrega,Nuria Lainez,L Rivera,R. Villatoro,Amaia Hernández,Alejo Rodriguez-Vida,Pedro P. Lopez-Casas,Enrique Gallardo Diaz,Elena Castro,David Olmos

Cabazitaxel versus enzalutamide/abiraterone in CARD eligible mCRPC patients with or without germline HRR defects.

2020

5554Background: The CARD trial proved that in mCPRC patients (pts), previously treated with docetaxel and an androgen-receptor signaling inhibitor (ARSi), cabazitaxel (CBZ) significantly improves p...

Keywords:

Physical therapy
Abiraterone
Enzalutamide
Oncology
Cabazitaxel
Germline
Internal medicine
Medicine

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations